Article

Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistance

2020-10-08

Abstract excerpt

The PI3K pathway is highly active in human cancers. The four class I isoforms of PI3K are activated by distinct mechanisms leading to a common downstream signaling. Their downstream redundancy is thought to be responsible for treatment failures of PI3K inhibitors. We challenged this concept, by mapping the differential phosphoproteome evolution in response to PI3K inhibitors with different isoform selectivity patt...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: a2597dd1-5956-51a0-af97-7bec227fbfa1
DOI: 10.1101/2020.10.08.313833

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistanceDOI 10.1101/2020.10.08.313833Read

Targeting PI3K in cancer: mechanisms and advances in clinical trialsSemantic proximity Read

Targeting PI3K in Cancer: Any Good News?Semantic proximity Read

A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells.Semantic proximity Read

The emerging role of PI3K inhibitors for solid tumour treatment and beyond.Semantic proximity Read

Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.Semantic proximity Read

Implication of PI3K/Akt pathway in pancreatic cancer: When PI3K isoforms matter?Semantic proximity Read

Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancersSemantic proximity Read

The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell LinesSemantic proximity Read

Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid TumorsSemantic proximity Read

PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancerSemantic proximity Read

Current State and Future Challenges for PI3K Inhibitors in Cancer TherapySemantic proximity Read

Strategies and techniques for preclinical therapeutic targeting of PI3K in oncology: where do we stand in 2024?Semantic proximity Read